OBJECTIVES: The aim of this study was to evaluate the inherent value of Vasomotor symptoms (VMS) treatment. METHODS: The nationwide, cross-sectional, face to face survey was conducted on 1500 menopausal women above the age of 40. Through 3 times of bidding games, the respondent completed the interview for their willingness to pay (WTP) for VMS treatment regarding a specific amount of money to return to the patient’s pre-VMS health status. The starting bids were 10,000 KRW, 30,000 KRW, 50,000 KRW, and 100,000 KRW. Following the bidding games, the respondent was asked an open ended question directly asking them to provide their maximum WTP. RESULTS: Among 1500 respondents who completed the questionnaire, the perimenopausal women were 987 (65.8%), the early postmenopausal women were 295 (19.7%), late postmenopausal women were 116 (7.7%), and surgical menopausal women were 102 (6.8%). Currently, the respondents’ monthly cost for their VMS management was 55,621 KRW. It included complementary and alternative medical cost, as well as direct medical cost. Maximum WTP throughout the open ended question was 43,463 KRW per month. It included only treatment cost. The current monthly cost for VMS management was associated with WTP. The current consumption below 30,000 KRW group replied their WTP as 35,357 KRW. On the other hands, the current consumption above 100,000 KRW group replied their WTP as 96,351 KRW. (p<0.05) The menopausal stage and the family income level were also associated with WTP. But it was not statistically significant. CONCLUSIONS: It was shown that the WTP for VMS treatment was above the treatment costs associated with hormone replacement therapy (HRT), the most widely used drugs to alleviate VMS. (The monthly cost of HRT was about 7832 KRW.) *1 USD=1127 KRW